| Literature DB >> 34150672 |
Lingyi Zeng1,2, Chengru Yang1,2, Jisheng Zhang1, Kewang Hu1,2, Jingbo Zou3, Jie Li1, Jianmin Wang1, Wan Huang1, Lining Yin1,2, Xiaoli Zhang1,2.
Abstract
Background: Due to the critical condition and poor immunity of patients, the intensive care unit (ICU) has always been the main hospital source of multidrug-resistant bacteria. In recent years, with the large-scale use of antibiotics, the detection rate and mortality of carbapenem-resistant Klebsiella pneumoniae (CRKP) have gradually increased. This study explores the molecular characteristics and prevalence of CRKP isolated from the ICU ward of a tertiary hospital in China.Entities:
Keywords: ST11; carbapenem-resistant Klebsiella pneumoniae; intensive care unit; molecular epidemiology; outbreak
Mesh:
Substances:
Year: 2021 PMID: 34150672 PMCID: PMC8208809 DOI: 10.3389/fcimb.2021.656070
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1ICU internal layout plan. The number represents the corresponding beds. (A–G) indicate different areas divided artificially.
Clinical characteristics of ICU patients.
| Clinical characteristic | N = (51) |
|---|---|
|
| 72 years (43–94years) |
|
| 41 (82%) |
|
| |
| A group | 13 (25.5%) |
| B group | 6 (11.8%) |
| C group | 8 (15.7%) |
| D group | 13 (25.5%) |
| E group | 5 (9.8%) |
| F group | 0 (0%) |
| G group | 6 (11.8%) |
|
| |
| Diabetes mellitus | 4 (7.8%) |
| Pulmonary disease | 45 (88.2) |
| Invasive operation | 44 (86.3) |
| Antibiotic exposure | 35 (68.6) |
|
| |
| Improvement | 7 (13.7%) |
| Mortality | 9 (17.6%) |
| Abandon treatment | 8 (15.7%) |
| Discharge request | 27 (52.9%) |
Figure 2CRKP genetic similarity and antibiotic sensitivity. IMP, Imipenem; MEM, Meropenem; ATM, Aztreonam; FEP, Cefepime; CAZ, Ceftazidime; CZO, Cefazolin; TZP, Piperacillin tazobactam; CIP, Ciprofloxacin; LEV, Levofloxacin; AK, Amikacin; PB, Polymyxin B; TIG, Tigecycline; CAZ–AVI, ceftazidime–avibactam.
Figure 3Distribution of MIC values of different types of antibiotics determined by broth micro-dilution method. MIC, the minimal inhibitory concentration; µg/ml, micrograms per milliliter; IMP, Imipenem; MEM, Meropenem; LEV, Levofloxacin; AK, Amikacin; PB, Polymyxin B; TIG, Tigecycline; CAZ–AVI, ceftazidime–avibactam.
Figure 4The carrying status of phenotype, drug resistance genes, virulence genes and homology heat map of CRKP.
Antibiotic susceptibilities of CRKP isolates and their transconjugants (µg/ml).
| Isolate | Resistance genes | MIC | ||||||
|---|---|---|---|---|---|---|---|---|
| IMP | MEM | AK | LEV | TIG | PB | CAZ–AVI | ||
| CRKP isolates | ||||||||
|
|
| 16 | 128 | >512 | 32 | <1/2 | 1 | 1,4 |
|
|
| 64 | 128 | >512 | 64 | 1 | 2 | 1,4 |
|
|
| 64 | 512 | >512 | 32 | <1/2 | 4 | 4,4 |
|
|
| 128 | 512 | >512 | 32 | <1/2 | 4 | 1,4 |
|
|
| 64 | 512 | >512 | 32 | 1 | 4 | 4,4 |
|
|
| 256 | 256 | <1/2 | 32 | 1 | 2 | 4,4 |
|
| ||||||||
|
|
| 4 | 4 | >512 | <1/2 | 1 | <1/2 | 1/2,4 |
|
|
| 4 | 4 | >512 | <1/2 | <1/2 | <1/2 | 1/2,4 |
|
|
| 4 | 16 | >512 | 1 | <1/2 | 1 | >256,4 |
|
|
| 8 | 8 | >512 | <1/2 | <1/2 | <1/2 | 1,4 |
|
|
| 16 | 16 | >512 | <1/2 | <1/2 | <1/2 | 1,4 |
|
|
| 4 | 4 | <1/2 | 1 | 1 | <1/2 | 1/2,4 |
IMP, imipenem; MEM, meropenem; AK, amikacin; LEV, levofloxacin; TIG, tigecycline; PB, polymyxin B; CAZ–AVI, ceftazidime–avibactam; µg/ml, micrograms per milliliter.
Figure 5A timeline represents the ICU stay of patients. Different colors in the legend indicate the different groups.